G

GlaxoSmithKline Pakistan Limited

PSX-GLAXO
Pakistan Stock Exchange NYSE
Healthcare Pharmaceuticals
Global Rank
#15043
Country Rank
#33
Market Cap
$420.17 M
Price
$1.32
Change (%)
0.00%
Volume
315,711

PSX-GLAXO's Next Dividend

Next Estimated Amount
rs10
Next Estimated Pay Date
05/05/2028
Last Amount
rs10
Last Pay Date
05/07/2025
Dividend Shot Clock Ex-Date: 04/18/2025
0
Days
0
Hours
0
Minutes
0
Seconds
Ex-dividend date passed

GlaxoSmithKline Pakistan Limited Dividend Chart

*Amounts are shown in the stock exchange currency (PKR) for convenience

GlaxoSmithKline Pakistan Limited(PSX-GLAXO) Dividend History

GlaxoSmithKline Pakistan Limited (PSX-GLAXO) currently pays an annual dividend of $10.00 per share, offering a dividend yield of 2.65%. The next dividend payout date has not been announced.
Ex-Dividend Date Adj. Amount Record Date Pay Date Change (%)
2025 rs10 43%
04/18/2025 rs10 04/21/2025 05/07/2025 43%
2022 rs7 8%
04/15/2022 rs7 04/18/2022 05/09/2022 8%
2021 rs6.5
04/19/2021 rs6.5 04/21/2021 05/06/2021
*Amounts are shown in the stock exchange currency (PKR) for convenience
*Historical information is adjusted for stock splits

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking
Community

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.